Clinical trial NCT02765594: Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
Official title: Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Primary IgA Nephropathy
Keywords: Glomerulonephritis, IGA
Kidney Diseases
Autoimmune Diseases
Glomerulonephritis
Nephritis
Immune System Diseases
Urologic Diseases
Hydroxychloroquine
Anti-Infective Agents
Antimalarials
Antiparasitic Agents
Antiprotozoal Agents
Antirheumatic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
interleukin-6
interferon-alpha
tumor necrosis factor-alpha
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2016-05-06
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis in the world.There is to date no curative therapy for patients with IgAN.It is considered that dendritic cells, Toll-like receptor (TLR) 9 and cytokines interleukin-6 (IL-6), and interferon-alpha (IFN-a) and tumor necrosis factor-alpha (TNF-α), play an important role in the aberrant mucosal response. Hydroxychloroquine is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting plasmacytoid dendritic cells, reduced production of inflammatory cytokines including interferon alpha, IL-6 and TNF alpha. Recent studies showed hydroxychloroquine had a benefit for renal remission and could retard the onset of renal damage in patients with lupus nephritis. hydroxychloroquine may have the potential effect in IgA nephropathy, alleviated the proteinuria and had the renal protect effect. This will be a single center, prospective, randomized, controlled study to assess the utility of hydroxychloroquine in IgAN patients.

Detailed description: Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis in the world. Its estimated frequency is at least 2.5 cases per year per 100,000 adults. The glomerulopathy usually progressed slowly leading to end stage renal disease (ESRD). ESRD developed in 20%-40% of patients after 20 years. Given its complex and as yet incompletely understood pathogenetic mechanisms, there is to date no curative therapy for patients with IgAN.

Although pathogenesis of IgAN is still obscure, underglycosylated IgA-containing immune-complex including IgG or IgA antibodies against the hinge region of IgA1 are key factors for IgA nephropathy. Aberrant mucosal immune response might lead to increased production of underglycosylated IgA1. It is considered that dendritic cells, Toll-like receptor (TLR)9, and cytokines interleukin-6 (IL-6), , interferon-alpha (IFN-a) and tumor necrosis factor-alpha (TNF-α), play an important role in the aberrant mucosal response.

Hydroxychloroquine is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting plasmacytoid dendritic cells, reduced production of inflammatory cytokines including interferon alpha, IL-6 and TNF alpha. Recent studies showed hydroxychloroquine had a benefit for renal remission and could retard the onset of renal damage in patients with lupus nephritis.

Therefore, hydroxychloroquine, targeting dendritic cells, TLR, IL-6, IFN-α and TNF-α，may have the potential effect in IgA nephropathy, alleviated the proteinuria and had the renal protect effect. This will be a single center, prospective, randomized, controlled study to assess the utility of hydroxychloroquine added to valsartan in IgAN patients.

Eligibility criteria: Inclusion Criteria:

1. biopsy proven primary IgA nephropathy
2. age 18-60 years
3. proteinuria range from 0.5 to 1.5g/d
4. serum creatinine ≤132.6μmol/L
5. normal blood pressure or blood pressure ≤130/80 mmHg in patients with hypertension

Exclusion Criteria:

1. Hypersensitivity to chloroquine or to hydroxychloroquine
2. blood pressure \<90/60 mm Hg
3. pregnancy and breastfeeding women
4. renal artery stenosis
5. Rapidly progressive renal insufficiency
6. systemic lupus erythematosus or other connective tissue diseases
7. Henoch- schoenlein purpura
8. other nephritis
9. diabetes mellitus
10. retinopathy
11. other contraindication of hydroxychloroquine
12. severe hepatic insufficiency
13. G6PD deficiency
14. psoriasis or porphyria
15. malignant hypertension
16. viral hepatitis or other infections
17. treatment with steroids or cytotoxic drugs during the previous three months
18. psychiatric disorder
19. not suitable for the study judged by investigator

Primary outcomes:
measure: Incidence of Remission (Complete [CR] or Partial [PR]) at Week 24
timeFrame: 24 weeks
Secondary outcomes:
measure: Change from Baseline in Proteinuria Levels at the Indicated Time Points
timeFrame: Baseline and Weeks 4, 12, 24
measure: Change from Baseline in Serum Creatinine Levels at the Indicated Time Points
timeFrame: Baseline and Weeks 4, 12, 24
measure: Change from Baseline in eGFR at the Indicated Time Points
timeFrame: Baseline and Weeks 4, 12, 24
measure: Change from Baseline in Serum IgA Levels at the Indicated Time Points
timeFrame: Baseline and Weeks 4, 12, 24
measure: Change from Baseline in Serum Interleukin-6 Levels at the Indicated Time Points
timeFrame: Baseline and Weeks 4, 12, 24
measure: Change from Baseline in Serum Interferon alfa Levels at the Indicated Time Points
timeFrame: Baseline and Weeks 4, 12, 24
measure: Change from Baseline in Serum Tumor Necrosis Factor alpha Levels at the Indicated Time Points
timeFrame: Baseline and Weeks 4, 12, 24
measure: Adverse Effects at the Indicated Time Points
timeFrame: Weeks 4, 12, 24
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peing Union Medical College Hospital
Study officials:
affiliation: Peking Union Medical College Hospital
name: RUITONG GAO, MD
role: STUDY_DIRECTOR
References: